替尼达普

**替尼达普**
臨床資料
ATC碼	M01AX23 (WHO) ;
法律規範狀態
法律規範	未上市;
识别信息
	IUPAC命名法 5-chloro-2-hydroxy-3-(2-thienylcarbonyl)-1H-indole-1-carboxamide; ;
CAS号	120210-48-2
PubChem CID	60712;
ChemSpider	54717 ;
UNII	9K7CJ74ONH;
KEGG	D06072 ;
ChEMBL	ChEMBL1097558 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID9046104 ;
化学信息
化学式	C14H9ClN2O3S
摩尔质量	320.75 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES c1cc(sc1)C(=O)c2c3cc(ccc3n(c2O)C(=O)N)Cl;
	InChI InChI=1S/C14H9ClN2O3S/c15-7-3-4-9-8(6-7)11(13(19)17(9)14(16)20)12(18)10-2-1-5-21-10/h1-6,19H,(H2,16,20) ; Key:IZSFDUMVCVVWKW-UHFFFAOYSA-N ;

替尼达普（INN：tenidap）^[1]是一种环氧合酶/5-脂氧合酶(COX/5-LOX)双效抑制剂和细胞因子调节消炎药候选药物^[2]。由辉瑞公司开发的具有治疗类风湿性关节炎前景的潜在药物^[3]。但因其肝肾毒性原因，1996年上市批准遭到美国FDA拒绝，辉瑞因此停止了对其开发^[4]。造成其肝肾毒性的原因是药物结构中含有噻吩基团的部分在体内代谢过程中会造成氧化损伤^[5]。

参考文献[编辑]

^ 刘治军,韩红蕾 (编). 华法林+替尼达普(warfarin+tenidap). 药物相互作用基础与临床第三版. 北京: 人民卫生出版社. 2019.
^ Wylie G, Appelboom T, Bolten W, Breedveld FC, Feely J, Leeming MR, et al. A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial. British Journal of Rheumatology. June 1995, 34 (6): 554–63. PMID 7543348. doi:10.1093/rheumatology/34.6.554.
^ Staff, American Journal of Nursing. Drug Watch: Tenidap Offers Arthritis Therapy Minus Toxicity AJN 1996 96(1):58
^ Pfizer. Sept 27, 1996 Press release: Pfizer To Halt Plans For Commercialization Of Tenidap For Rheumatoid Arthritis 互联网档案馆的存檔，存档日期2016-03-05.
^ Hwang SH, Wecksler AT, Wagner K, Hammock BD. Rationally designed multitarget agents against inflammation and pain. Current Medicinal Chemistry. 2013, 20 (13): 1783–99. PMC 4113248 . PMID 23410172. doi:10.2174/0929867311320130013.

[1] 刘治军,韩红蕾 (编). 华法林+替尼达普(warfarin+tenidap). 药物相互作用基础与临床第三版. 北京: 人民卫生出版社. 2019.

[2] Wylie G, Appelboom T, Bolten W, Breedveld FC, Feely J, Leeming MR, et al. A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial. British Journal of Rheumatology. June 1995, 34 (6): 554–63. PMID 7543348. doi:10.1093/rheumatology/34.6.554.

[3] Staff, American Journal of Nursing. Drug Watch: Tenidap Offers Arthritis Therapy Minus Toxicity AJN 1996 96(1):58

[4] Pfizer. Sept 27, 1996 Press release: Pfizer To Halt Plans For Commercialization Of Tenidap For Rheumatoid Arthritis 互联网档案馆的存檔，存档日期2016-03-05.

[pmid23410172-5] Hwang SH, Wecksler AT, Wagner K, Hammock BD. Rationally designed multitarget agents against inflammation and pain. Current Medicinal Chemistry. 2013, 20 (13): 1783–99. PMC 4113248 . PMID 23410172. doi:10.2174/0929867311320130013.

[1]

[2]

[3]

[4]

[5]